OCEA Ocean Biomedical: Price-to-Projected Revenue Ratio
Ocean Biomedical, Inc. (OCEA) maintains business resilience through FDA patents and Brown University licenses. The forward price-to-sales ratio on GURU.Markets reflects the valuation trend, where represents the latest metric reading. The company relies on a closed-loop antibody system to combat cancer and malaria, attracting top researchers through a commercialization system for their scientific discoveries.
Metric breakdowns and analytics for Ocean Biomedical Corp (OCEA)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and liquidity data:
Total Debt to Capital Ocean Biomedical, Inc.|OCEA - Long-Term Debt to Capital|Short-Term Debt to Equity Ocean Biomedical, Inc.|OCEA - Company Aggregate Debt|Debt to Book Value Ocean Biomedical Corp|OCEA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Ocean Biomedical|Quick Ratio oceanbiomedical.com
- financial results and valuation multiples details:
OCEA - Net Financial Result|Expected Profit Ocean Biomedical, Inc.|OCEA - Market Cap to Earnings|Future Price to Earnings Ocean Bio|OCEA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Ocean Biomedical Corp|OCEA - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Ocean Biomedical|OCEA - Earnings per share for the last 12 months|Quarterly EPS earnings growth oceanbiomedical.com|OCEA - Expected net earnings per share growth this year|Earnings growth forecast for next year Ocean Biomedical, Inc.
- sales and revenue data:
Fundamental company valuation:Ocean Biomedical (OCEA)
When constructing a long-term portfolio, it is critical to correlate market capitalization with expected revenue to determine an asset's degree of overvaluation. The forward P/S ratio measures a company's value relative to projected sales, which allows for an assessment of Ocean Biomedical, Inc. (OCEA) expansion potential in oncology through the scaling of B2B partnerships by tracking price momentum on this chart.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio ADMA Corp|PTGX: Forward P/S Multiple|Forward Price-to-Revenue Multiple immunovant.com|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Forward P/S Multiple ADPT|Forward P/S Multiple Celldex Corp (CLDX)|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|BCRX: Market Cap to Projected Revenue|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS: Forward P/S Multiple|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|precigen.com (PGEN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Pharming Group (PHAR)|NKTR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|ZBIO - Forward Price-to-Revenue Multiple|Immunome, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio gossamerbio.com|KALV: Forward P/S Multiple|Market Cap to Projected Revenue SEPN|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Savara Pharma (SVRA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|Forward P/S Multiple enGene Holdings Inc ENGN|RAPT - Price-to-Projected Revenue Ratio|JBIO: Price-to-Projected Revenue Ratio|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|kyvernatx.com - Forward Price to Sales|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Ventyx Bio (VTYX)|Theratechnologies, Inc - Market Cap to Projected Revenue|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|ELDN - Forward Price-to-Revenue Multiple|AGEN: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Climb Bio Inc. CLYM|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio aTyr Pharmaceuticals (ATYR)|ADAG (Adagene Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ikena Oncology, Inc. (IMA)|Forward P/S Multiple STTK|EQ - Market Cap to Future Revenue Ratio|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|Future Price to Revenue IFRX|XFOR: Forward P/S Multiple|Adicet Bio, Inc. - Forward Price to Sales|CELU (Celularity Inc) - Forward P/S Multiple|Forward P/S Multiple INmune Bio Corporation|Price-to-Projected Revenue Ratio Barinthus Biotherapeutics (BRNS)|KZR (kezarlifesciences.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio SAB Biotherapeutics, Inc. SABS|AKTX - Forward Price-to-Revenue Multiple|Enlivex Therapeutics, Ltd. - Forward P/S Multiple|QTTB - Forward P/S Multiple|GOVX (GeoVax Labs, Inc.) - Forward Price-to-Revenue Multiple|edesabiotech.com - Forward Price to Sales|IBIO (iBio) - Forward P/S Multiple|Carisma Tx (CARM) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|Forward Price-to-Revenue Multiple boltbio.com BOLT|Price-to-Projected Revenue Ratio HCW Biologics HCWB|APVO - Forward Price-to-Revenue Multiple|AIM: Forward Price-to-Revenue Multiple|ADTX - Forward P/S Multiple|GRI Bio Corp (GRI) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue XRTX|HIND (Vyome Holdings Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revbiosciences.com REVB|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|SCNI - Market Cap to Future Revenue Ratio|Forward P/S Multiple CALI (CalciMedica)|AFMD - Forward Price-to-Revenue Multiple|Allakos Therapeutics - Forward P/S Multiple|Market Cap to Future Revenue Ratio HOOKIPA Pharma Inc.|IGMS: Forward P/S Multiple|iTeos Therapeutics Inc (ITOS) - Forward P/S Multiple|Price-to-Projected Revenue Ratio TC BioPharm (Holdings) PLC|Market Cap to Projected Revenue THRD (Third Harmonic Bio Inc)
